School of Medicine
Showing 1-2 of 2 Results
Postdoctoral Research Fellow, Stanford Cancer Center
Bio Zinaida Good, Ph.D. is a 2020 Stanford Cancer Institute Fellow training with Profs. Crystal L. Mackall, M.D. and Sylvia K. Plevritis, Ph.D. at Stanford University. Dr. Good’s research is focused on investigating how chimeric antigen receptor (CAR)-expressing T lymphocytes succeed or fail in patients, in order to guide the design of the next generation of engineered cell therapies. Leveraging multimodal single-cell data analysis, tumor microenvironment imaging, and data integration, she aims to identify features of optimal CAR T cells from patient data. Her projects include: (1) identification of CAR T-cell populations that are associated with durable complete response in diffuse large B-cell lymphoma (DLBCL) patients receiving a CD19-targeted therapy Axicabtagene ciloleucel; (2) defining features of successful CAR T-cell clones in DLBCL patients receiving bispecific CD19/CD22-targeted CAR T cells on a Stanford trial; and (3) identifying modulation points to improve CAR T-cell function within the tumor microenvironment in DLBCL and solid tumors. Dr. Good earned her Ph.D. in Computational & Systems Immunology from Stanford University in April 2018, where she trained with Profs. Garry P. Nolan, Ph.D. and Sean C. Bendall, Ph.D. Her background is in immunology (B.S. and M.S. from the University of British Columbia in Vancouver, Canada) and oncology (she worked for 2 years in Discovery Oncology at Genentech). As a result of her academic training and work experiences, Dr. Good became an inventor on 2 patent applications, co-authored 7 papers, and wrote 3 first-author manuscripts (Good and Sarno et al. Nature Medicine, 2018; Good et al. Nature Biotechnology, 2019; Good et al. Trends in Immunology, 2019). Her long-term interest is in the systems-level events required for a coordinated immune attack against cancer.